Syngene International Ltd, the research and development unit of biopharmaceutical firm Biocon Ltd, said on Monday it has appointed Jonathan Hunt as CEO.
Hunt will take charge after Peter Bains retires from the post in March, Syngene said in a stock market disclosure. Hunt is currently president at AstraZeneca Plc Austria.
Bains, who was appointed as CEO in February 2015, will continue as a member of Syngene’s board.
Kiran Mazumdar-Shaw, managing director at Syngene, said Hunt has a proven track record of leading transformational change and delivering growth.
Prior to Syngene, Hunt worked with AstraZeneca in various leadership positions including president and COO of its India unit.
Syngene is a contract research organisation offering a suite of integrated, end-to-end discovery and development services for novel molecular entities to companies in pharmaceutical, biotechnology, agrochemicals, consumer health, animal health, cosmetic and nutrition sectors.
The company made a strong stock market debut last year after raising Rs 550 crore in its initial public offering. The company’s shares were trading around Rs 411 apiece in late afternoon on Monday, about 64 per cent higher than the issue price of Rs 250.
Leave Your Comment
3 years ago
Syngene International, a subsidiary of biopharmaceutical major Biocon Ltd, has...
3 years ago
Biopharmaceutical major Biocon Ltd has fixed the price band for the initial...
4 years ago
Syngene International, a subsidiary of Biocon Ltd, a generics major that also...